SEC Form 4 · accession 0001209191-15-082995

Arcadia Biosciences, Inc. · RKDA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Scientific Officer

Period of report

Dec 1, 2015

Accepted (ET)

Dec 2, 2015 · 6:44 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001469443

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Dec 1, 2015	M	6,300	$1.08	A	53,434	D
Common Stock^F2	Dec 1, 2015	S	6,300	$3.8889	D	47,134	D
Common Stock	Dec 2, 2015	M	8,700	$1.08	A	55,834	D
Common Stock^F3	Dec 2, 2015	S	8,700	$4.0959	D	47,134	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (right to buy)^F4	$1.08	Dec 1, 2015	M	6,300	D	—	Jun 30, 2018	Common Stock	6,300	246,200	D
Employee Stock Option (right to buy)^F4	$1.08	Dec 2, 2015	M	8,700	D	—	Jun 30, 2018	Common Stock	8,700	237,500	D

F1The security transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Stock Trading Plan (the "Plan"), adopted by the Reporting Person effective June 12, 2015.
F2This transaction was executed in multiple trades at prices ranging from $3.78 to $3.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3This transaction was executed in multiple trades at prices ranging from $3.91 to $4.24. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4The option is fully exercisable as of the date hereof.